Century Therapeutics: A Biotech With Interesting Optionality Opportunities [Seeking Alpha]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Seeking Alpha
IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813 for Type 1 diabetes, now the pipeline's main value driver. Recent management actions reduced quarterly cash burn from $35M to $20M, extending runway to Q1 2028 after a 134% dilutive PIPE. Valuation via rNPV and Monte Carlo simulation yields a fair value of $2.61–$2.78 per share, with CNTY-813 contributing 69% of pipeline value. Dragos Condrea/iStock via Getty Images Investment Thesis I value Century Therapeutics ( NASDAQ: IPSC ) with a speculative buy rating. The company has undergone a pivotal restructuring in its pipeline, deprioritizing oncology programs in favor of autoimmune CAR cells and the innovative
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics (IPSC) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- Century Therapeutics (IPSC) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Century Therapeutics (IPSC) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics Reports Full Year 2025 Financial Results and Business UpdatesGlobeNewswire
IPSC
Earnings
- 11/13/25 - Miss
IPSC
Analyst Actions
- 4/21/26 - HC Wainwright
IPSC
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form PRE
- 4/10/26 - Form 4
- IPSC's page on the SEC website